Skip to main content
Clinical Trials/NCT01804231
NCT01804231
Completed
Not Applicable

A Prospective Study of Hybrid PET/MRI in the Evaluation of Men With Suspected Prostate Cancer Recurrence Following Definitive Local Therapy

Lawson Health Research Institute1 site in 1 country22 target enrollmentJuly 9, 2013
ConditionsProstate Cancer

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Prostate Cancer
Sponsor
Lawson Health Research Institute
Enrollment
22
Locations
1
Primary Endpoint
Frequency in change of clinical management based on results of 18F-FCH PET/MRI
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

Evaluate the impact of hybrid 18F-Fluoro-choline (18F-FCH) PET/MRI imaging on the clinical management of men with suspected recurrent prostate cancer post prostatectomy or radiotherapy.

We hypothesize that hybrid imaging incorporating 18F-FCH PET/MRI imaging will be feasible and will lead to changes in management decisions among men being re-staged for suspected prostate cancer recurrence post-surgery or radiation who are potentially eligible for local salvage therapy.

Detailed Description

The study will be a non-randomized, prospective study of men with suspected local recurrence of prostate cancer post-prostatectomy or radiation with negative bone and CT scans. Hybrid PET/MRI using 18F-FCH will be obtained and a consensus staging report generated for the attending clinician. Clinical management questionnaires completed by the study investigator will be obtained pre and post imaging in order to gauge the impact of the hybrid imaging on clinical decision making.

Registry
clinicaltrials.gov
Start Date
July 9, 2013
End Date
October 12, 2016
Last Updated
7 years ago
Study Type
Interventional
Study Design
Single Group
Sex
Male

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Prostate cancer with rising prostate specific antigen (PSA) post prostatectomy or radiotherapy
  • Suspected recurrence based on PSA rise measured on 3 occasions at least 3 months apart and an absolute PSA \> 0.2 ng/mL
  • Bone scan and CT scan of the abdomen and pelvis negative for metastatic disease

Exclusion Criteria

  • Evidence of metastatic disease
  • Contradiction to 18F-FCH PET scan
  • Contraindication to MRI

Outcomes

Primary Outcomes

Frequency in change of clinical management based on results of 18F-FCH PET/MRI

Time Frame: Within 2 weeks of study scan

A questionnaire to assess the planned management will be completed by the investigator before and after provision of the results of the 18F-FCH PET/MRI to determine if the information provided by 18F-FCH PET/MRI influences the preferred plan of management

Secondary Outcomes

  • Number of lesions identified with 18F-FCH based on consensus reporting(Within 2 weeks of study scan)

Study Sites (1)

Loading locations...

Similar Trials